Market closedNon-fractional

Arcturus Therapeutics Holdings/ARCT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Arcturus Therapeutics Holdings

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.

Ticker

ARCT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

180

ARCT Metrics

BasicAdvanced
$591M
Market cap
-
P/E ratio
-$4.02
EPS
2.76
Beta
-
Dividend rate
$591M
2.76
3.256
2.733
10.475
12.093
-5,107.17%
-17.22%
-36.17%
4.704
2.23
2.23
59.982
-55.69%
-198.54%
139.89%
-7.65%

What the Analysts think about ARCT

Analyst Ratings

Majority rating from 9 analysts.
Buy

ARCT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-70.52% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$38M
23.38%
Net income
-$27M
129.06%
Profit margin
-70.52%
85.68%

ARCT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.88%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.98
-$0.61
-$0.32
-$1.00
-
Expected
-$0.21
-$1.69
-$0.99
-$1.19
-$1.58
Surprise
839.50%
-63.94%
-67.75%
-15.88%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Arcturus Therapeutics Holdings stock?

Arcturus Therapeutics Holdings (ARCT) has a market cap of $591M as of July 05, 2024.

What is the P/E ratio for Arcturus Therapeutics Holdings stock?

The price to earnings (P/E) ratio for Arcturus Therapeutics Holdings (ARCT) stock is 0 as of July 05, 2024.

Does Arcturus Therapeutics Holdings stock pay dividends?

No, Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Arcturus Therapeutics Holdings dividend payment date?

Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders.

What is the beta indicator for Arcturus Therapeutics Holdings?

Arcturus Therapeutics Holdings (ARCT) has a beta rating of 2.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Arcturus Therapeutics Holdings stock

Buy or sell Arcturus Therapeutics Holdings stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing